Menu Contact Us Home Capabilities Our Team In The Media LifeSci Partners Copyright 2021 LifeSci Communications Blog

Clients in the Media LifeSci Communications Clients in the Media

Rogue antibodies could be driving severe COVID-19

Finding a rock-solid connection can be tough, because it’s difficult to show whether the infections are the cause of autoimmune disorders or whether they crop…

READ MORE

Clene Nanomedicine Aims to be the ‘Gold Standard’ in Neurodegenerative Disease

Clene Nanomedicine, one of Maryland’s Future 2020 companies, closed a merger with Tottenham Acquisition I Limited that provided the company with a slot on the…

READ MORE

Disease-cancelling drugs: Immuneering raises $62m in Series B round

Immuneering has raised $62m in an oversubscribed Series B round led by high-profile life science investors. The money will be used to support the company’s…

READ MORE

JPM: Aridis CEO Truong on why the pandemic hasn’t bolstered antibiotics R&D and what needs to change

With its pipeline of bacteria-fighting monoclonal antibodies, Aridis is working to tackle the first two problems: injecting innovation into the space and testing its programs…

READ MORE

Here’s What 4 Biopharma CFOs Think About The Future Of Remote Work

Office interactions are definitely an important way to foster relationships between coworkers, establish and maintain a corporate culture, and foster creative thinking. This is particularly…

READ MORE

Biopharma Executive Perspectives on 2021

“The biggest thing that is really happening in the biotech industry…there is a new rich source of drugs. There is a goldmine, called mRNA, that…

READ MORE

Health-Care Venture Capitalists Raised Record Total in 2020

Immuneering Corp., a Cambridge, Mass.-based startup that uses computational technology for drug discovery, completed a $62 million Series B round. Cormorant Asset Management led the…

READ MORE

Using Computational Discovery to Build Better Immunotherapies

Compugen is using a computational discovery platform to identify proteins and pathways that drive immune resistance mechanisms to checkpoint inhibitors. We spoke to Anat Cohen-Dayag,…

Listen here

What We Know About Narcolepsy, Sodium Oxybate Use, Salt Intake & Cardiovascular Risk

The review received financial support from Avadel Pharmaceuticals, which recently filed a new drug application  with the US Food & Drug Administration (FDA) for a…

READ MORE

Immuneering secures $62M series B to advance tech-driven pipeline

Immuneering Corp., a bioinformatics specialist that has for years helped big companies like Teva Pharmaceutical Ltd. and Bristol Myers Squibb Co. better understand their own…

READ MORE

Clene goes public with gold-based neurology nanotechnology

Biotech Clene Nanomedicine has gone public with a mission to use nanotherapeutics that will use gold to treat devastating neurological diseasesincluding Parkinson’s disease.

READ MORE

Immuneering, Terns raise crossover rounds as IPO queue stands to grow again

With crossover investors lining up to participate, biotechs Immuneering and Terns each raised…

READ MORE

Using Protein Characterization to Support Regulatory Submissions

Before any biologic drug enters into the clinic, it is essential to have a clear understanding of what exactly the biomolecule entails, according to Vu…

READ MORE

New and Emerging Drug Classes That Will Outlast the Pandemic

OncoSec’s vaccine, CORVax12, being developed in partnership with Providence Cancer Center in Portland, uses a DNA-encodable stabilized trimeric SARS-CoV-2 spike glycoprotein developed in the National…

READ MORE

A year in Longevity: science perspectives

August was also Healthy Aging Month and, to get some perspective on the topic, we spoke to Stanford’s Dr Thomas Rando, best known for his…

READ MORE

Dr. Ragan Discusses X4’s Work To Advance Disease-Modifying For Rare Genetic Diseases | Podcast

Dr. Ragan discusses X4 Pharmaceuticals, which is currently developing therapies for rare genetic diseases that result from dysfunction of the immune system and is currently…

View clip

Developing Effective COVID-19 Oral Vaccine in Tablet Form with Sean Tucker Vaxart

Sean Tucker, Founder and Chief Scientific Officer, Vaxart is on a mission to expand the choices for a COVID-19 vaccine by producing an effective oral…

Listen here

Peptidream, Amolyt alliance focuses on potential acromegaly treatment

Peptidream Inc. inked a research collaboration with Amolyt Pharma SAS to test and optimize Peptidream’s growth hormone receptor antagonist (GHRA) peptides, with the aim of…

READ MORE

X4 Pharma Adjusts Clinical Trials For A COVID World

X4 Pharma is a company focused on delivering innovative treatments for patients with rare diseases of the immune system. With the COVID pandemic afflicting patients…

READ MORE

Seneca Biopharma merges with Leading BioSciences, becoming Palisade Bio

Penny stock biotech Seneca Biopharma has found a lifeline in privately owned Leading BioSciences as it merges with the biotech.

READ MORE

Dr. CJ Barnum of INmune Bio | NIH Grant tests Neuroinflammation on Treatment Resistent Depression

We sit down with Dr. CJ Barnum, Director of Neuroscience at Inmune Bio, Inc. to talk about the recently announced grant from the NIH for…

View clip

Buffalo-formed company Athenex gets FDA approval for cancer drug

Buffalo-formed biopharmaceutical company Athenex just got FDA approval for a topical ointment to treat it, called Klisyri.

READ MORE

Sio Gene Therapies posts positive PhI/II data in rare pediatric disease, the first readout since its name change

A little over a month after a full company rebrand, the Biotech Formerly Known as Axovant has its first data readout under its new moniker.

READ MORE

Bypassing Bioprocessing in Antibiotic Production

Scientists at Recce design these antibiotics to attach to proteins in the plasma membrane of pathogens via hydrophobic interactions, which trigger cell lysis. “The bacteria…

READ MORE

6 CEOs Weigh In On The Supply Chain, Nationalism, And The Reshoring Of Biopharma Manufacturing

At a macro level across the globe, there is an increasing cadence, on an exponential curve, in the ability to translate basic insights into therapeutics.…

READ MORE

The Editors’ views: Drug Target Review’s 2020 round-up

GigaGen Inc.’s co-founder and Chief Executive Officer, explained that for decades scientists working with emerging pathogens had been concerned about the possibility of a pandemic,…

READ MORE

The Race Against Mutation: How Vaccines Will Keep Up as the Coronavirus Evolves

One such company is Vaxart, based in South San Francisco, which is currently in Phase 1 human trials for a COVID-19 vaccine that’s taken as…

READ MORE

Aridis’ At-Home COVID-19 Therapy and Other Programs Primed for 2021 Inflections

Next year could be pivotal for Aridis. It anticipates inflection points for three immunotherapy programs and is making available for licensing its rapid mAb development…

READ MORE

Rocket Pharmaceuticals Surges To 5-Year High On Promising Gene Therapy

Rocket Pharmaceuticals (RCKT) announced positive Phase 1 test results for a gene therapy in heart disease — prompting RCKT stock to surge Wednesday.

READ MORE

Biotechs Developing Innovative Ways to Activate the Immune System Against COVID-19

Abpro Corp., a biotechnology company developing next generation antibody therapies for severe disease, is targeting a more robust antibody response with its therapeutic, ABP 300,…

READ MORE

Latest data give Rocket clear path forward in rare CV disease Danon

While an adverse event in the high-dose cohort continues to outline the limits oh high volume AAV dosing…

READ MORE

View From The Inside: What’s Shaping Biopharma In 2021 And Beyond?

About a year ago, Life Science Leader Chief Editor Rob Wright posed questions to several biopharma leaders for a column in the 2019 iteration of this annual…

READ MORE

2020 Top 10 Innovations

Enter GigaGen’s Surge platform, which uses single-cell sequencing to “capture and recreate” libraries of antibodies from blood donors.

READ MORE

Trial Drug Shows Promise in Treating Cognitive Impairment Associated with Schizophrenia

Last week, privately-owned Cerevance released data from a Phase Ib biomarker study of its oral compound, CVN058, evaluating the potential of the medication as a…

READ MORE

Genetic medicines find a heartbeat

“RNA interference is often better than antibodies because of the catalytic process that you can generally use,” said Chris Anzalone, CEO of Arrowhead Pharmaceuticals. A…

READ MORE

Emerging fungal resistance: A hidden epidemic

Invasive fungal infections are becoming increasingly common and often pose a serious public health threat, claiming the lives of more than 1.5 million people worldwide…

READ MORE

New Class of Drugs Harnesses Gold Nanocrystals to Heal and Protect the Brain

Clene Nanomedicine is trying to set a new “gold standard” in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics…

READ MORE

Targeting Calcium Overload Could Improve Stroke Outcomes

“We are fortunate to collaborate with CalciMedica, a pharmaceutical company who specializes in developing drugs suppressing calcium overload in the immune cells,” Tvrdik said. “We…

READ MORE

Scientists race to find ‘warm’ Covid vaccine to solve issue of cold storage

Vaxart, a San Francisco-based biotechnology company, is testing a tablet-form Covid-19 vaccine to tackle storage temperature problems, which affect even rich countries like the US,…

READ MORE

One Fourth of Maryland’s Future 20 are Life Science Companies

Clene Nanomedicine is a clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases. Its chief asset is CNM-Au8, a bioenergetic nanocatalyst under development as an add-on…

READ MORE

Treating Cognitive Impairment in Patients with Schizophrenia

The drug in question, Cerevance, significantly improved cognitive impairments in patients suffering from schizophrenia. Dr Margolin discusses the structure of the drug trail, details the…

READ MORE

New Oncology Therapies Emerge Amidst COVID Pandemic

Cue Biopharma has managed to persevere through the COVID pandemic by employing a variety of strategies. President and Chief Scientific Officer, Anish Suri, and Ken…

READ MORE

Chiasma set for EMA filing based on acromegaly data

Chiasma was trading 4% higher in the opening minutes on Wednesday.

READ MORE

Cerevance buoyed by postive clinical trial results for schizophrenia compound

Cambridge Science Park-based Cerevance has confirmed positive results from a trial of a potential treatment for cognitive impairment associated with schizophrenia.

READ MORE

Blocking Neuroinflammation

Christopher J. Barnum, PhD, of INmune Bio, Inc discusses XPro1595, developed by INmune Bio, and how it may provide neuroprotective benefits for those at risk…

READ MORE

OSE details novel immuno-oncology strategy targeting ‘don’t eat me’ signaling in cancer

OSE Immunotherapeutics is among the companies pursuing this signaling pathway, and it has unveiled preclinical data supporting a novel strategy for disrupting it.

READ MORE

8 Biotech Startup Lessons From Heat Bio’s Jeff Wolf

Any time we have an opportunity to talk with Jeff Wolf, we take it – especially when the conversation tackles the highs and lows of…

READ MORE

New Animal Data Shows Promise for Vaxart’s Oral COVID-19 Vaccine

Vaxart announced new data from its Hamster Challenge Study today, showing that its oral COVID-19 vaccine candidate can potentially reduce viral load and induce a…

READ MORE

Can Valneva Do What SmithKlineBeecham Couldn’t?

As marketability goes—and despite a growing unmet medical need—Lyme disease vaccine programs have suffered a futile fate. With its VLA15 candidate, French specialty vaccine company…

READ MORE

Pfizer data very hopeful, gives US evidence a vaccine is possible: Researcher

Nantkwest Executive Chairman Dr. Patrick Soon-Shiong weighs in on Pfizer data and discusses the coronavirus vaccine trial process.

View clip

‘We’re not a van­t’: Ax­o­vant seeks to for­get the past as the com­pa­ny re­brands to Sio Gene Ther­a­pies

Aiming to shed the legacy of an epic Alzheimer’s fail a few years ago, Axovant $AXGT is changing its name in a full corporate rebrand.…

READ MORE

Triangle research facilities help with trials for promising Pfizer COVID-19 vaccine

Heat Biologics in Research Triangle Park is also working on a vaccine to combine with one like Pfizer’s to generate a more robust immune response.

READ MORE

Jewish Hospital treats first patient in national COVID-19 drug trial

Jewish Hospital has treated its first patient as part of a national study that hopes to prevent the progression of pulmonary complications due to COVID-19.

READ MORE

Study of COVID treatment Quellor has first patient at Louisville hospital

Though a COVID-19 vaccine could be released by year’s end or soon after, healthcare professionals say getting it to everyone who needs it is expected…

READ MORE

Biomarkers Show the Power of Contexualization

Two genetic signatures that Rain Therapeutics scientists are focusing on are MDM2 gene amplification and wild-type p53 status, which tend to be exclusive events in…

READ MORE

Clover Biopharma nabs $250M-plus for COVID-19 vaccine in expanded CEPI deal

China’s Clover Biopharma is getting another boost as it gears up for a global, pivotal trial of its COVID-19 vaccine. The Coalition for Epidemic Preparedness…

READ MORE

Vaxart Has Developed the First Oral Investigational COVID-19 Vaccine

South San Francisco-based Vaxart recently announced they had entered into a phase 1 trial for their VXA-CoV2-1 vaccine. Vaxart is a biotechnology company developing a range…

READ MORE

The Making Of A Pharma CEO

Paula Ragan, Ph.D., is one of those leaders and one of a select group who not only was mentored by Termeer — an industry legend…

READ MORE

Targeting PVRIG in cancer immunotherapy

Compugen Ltd. recently presented new research data further supporting the PVRIG protein coding gene as a potentially promising target for cancer immunotherapy. These data suggest that…

READ MORE

Novel drug may provide symptom control in hypoparathyroidism

Several analogues of parathyroid hormone in different formulations are being developed to provide more long-lasting effects of the molecule. AZP-3601 (Amolyt Pharma) is one of…

READ MORE

An Inhalable mAb For COVID-19?

Aridis Pharmaceuticals founder, CEO, and Director Vu Truong, Ph. D. doesn’t think the 8,000 milligram dose of Regeneron’s SARS-CoV-2 Virus Multi-Antibody Therapy (REGN-COV2) given to…

READ MORE

Biotech Veteran Developing Natural Hormones for Orphan Indications

On October 14th, Amolyt Pharma announced the first dosing in its Phase I trial of AZP-3601 in healthy subjects, a momentous occasion capping off years of hard…

READ MORE

9 Meters Biopharma targeting rare and unmet needs in GI disorders

9 Meters Biopharma (NASDAQ: NMTR) expects to report clinical trial data readouts in 2021 from two gastrointestinal disorders: short bowel syndrome, an underserved and debilitating rare…

READ MORE

Silencing gene expression to cure complex diseases

Immuneering uses bioinformatics to develop new medicines while also helping large pharmaceutical companies improve their treatments.

READ MORE

Woburn-based biotech company seeing promising results in COVID-19 antibody treatment

A Woburn-based biotech company says it’s seeing early success with COVID-19 antibody treatments. Scientists at Abpro have been studying antibodies for a decade but the…

View clip

Execs Weigh In On Presidential Politics Impacting Biopharma

We at NeuBase have felt that there are fundamental deficiencies in the current approach to drug development. The traditional drug screening approach, which involves scouring…

READ MORE

Immunitybio to begin phase one testing of COVID-19 vaccine candidate

Immunitybio Chairman and CEO Dr. Patrick Soon-Shiong joins ‘Maria Bartiromo’s Wall Street’ to discuss

View clip

Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic

A couple months after raising CHF 2.5 million ($2.76 million) in initial seed funding, one-year-old Araris Biotech is topping off the round with another CHF…

READ MORE

Ensuring Patient-Friendly Clinical Trials For Complex Disorders — A Small Biopharma’s Playbook

Rezolute, a small company based in Redwood City, California, and working in the rare pediatric disease space, is developing a new therapeutic option specifically for…

READ MORE

First Person Treated in Amolyt Pharma’s AZP-3601 Trial for Hypoparathyroidism

Amolyt Pharma, formerly Alizé Pharma 3, had announced earlier this year its plans to start a clinical trial of AZP-3601 by the end of 2020.

READ MORE

Inhaled antibody drug for COVID-19 clears coronavirus in animals

Aridis Pharmaceuticals is working on an inhaled neutralizing antibody for COVID-19 dubbed AR-711, which was discovered using samples from patients who had recovered from COVID-19.…

READ MORE

HQ Move Fuels Fountain’s AI Drug Discovery Machine

Fountain Therapeutics’ unique AI discovery platform prompted an invitation from Eli Lilly & Company to move Fountain headquarters to Lilly Gateway Labs. Company CEO Dr.…

READ MORE

SMA, NMOSD and Aging – From Few to Everyone

Moira speaks with Dr. Levi Garraway, the Chief Medical Officer of Genentech about FDA approvals for treatments in two very rare diseases – SMA –…

Listen here

Scynexis submits NDA for oral ibrexafungerp for vaginal yeast infection

Scynexis announced today that it has submitted a new drug application to the FDA for oral ibrexafungerp for the treatment of vulvovaginal candidiasis, the second…

READ MORE

Mark Erlander of Cardiff Oncology, Inc. Discusses KRAS Mutations in Cancer

Mark Erlander, Chief Executive Officer at Cardiff Oncology, Inc. talks KRAS mutations in cancer, and existing products like mCRC, mCRPc and AML, along with three…

Listen here

Antiviral Conjugates – A Novel Treatment and Prevention Strategy for Viral Diseases Including COVID-19

Cidara Therapeutics has adopted key immuno-oncology principles and applied them to infectious disease, enabling the creation of a novel antiviral strategy – antiviral conjugates (AVCs). AVCs…

READ MORE

Oral coronavirus vaccine candidate enters clinical trial

An oral coronavirus vaccine candidate has entered the clinical trial phase, bringing with it a possible option for those wary of needles. Vaxart Inc. announced on Tuesday that the…

READ MORE